| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Consumer health outlet |
| Population | Women |
| Source | Meto |
| URL | meto.co/blog/hormone-pellets-menopause-pros-cons (opens in a new tab) |
Specific Claim Evaluated
Testosterone in women has 1 strong evidence-based indication, hypoactive sexual desire disorder, and pellet insertion carries procedural risks including infection, bleeding, scarring and extrusion.
Primary Research Supporting or Contradicting the Claim
Testosterone improves sexual function in postmenopausal women with low desire and distress (Islam et al., 2019); the consensus statement does not support use for other indications and advises against pellets (Davis et al., 2019).
Corrected Evidence-Based Interpretation
Accurate.
Rationale for Grade
The article identifies the single supported indication and lists recognized procedural complications without overstating them. It is medically reviewed and does not promote pellet therapy. The content is consistent with meta-analytic and consensus evidence.
References
- Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID
Supporting excerpt: "The only evidence-based indication for testosterone for women is for HSDD." - Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766. PMID
Supporting excerpt: "Testosterone is effective for postmenopausal women with low sexual desire causing distress"